Emerging antiviral drugs

Expert Opin Emerg Drugs. 2008 Sep;13(3):393-416. doi: 10.1517/14728214.13.3.393.


Foremost among the newly described antiviral agents that may be developed into drugs are, for the treatment of human papilloma virus (HPV) infections, cPrPMEDAP; for the treatment of herpes simplex virus (HSV) infections, BAY 57-1293; for the treatment of varicella-zoster virus (VZV) infections, FV-100 (prodrug of Cf 1743); for the treatment of cytomegalovirus (CMV) infections, maribavir; for the treatment of poxvirus infections, ST-246; for the treatment of hepatitis B virus (HBV) infections, tenofovir disoproxil fumarate (TDF) (which in the meantime has already been approved in the EU); for the treatment of various DNA virus infections, the hexadecyloxypropyl (HDP) and octadecyloxyethyl (ODE) prodrugs of cidofovir; for the treatment of orthomyxovirus infections (i.e., influenza), peramivir; for the treatment of hepacivirus infections (i.e., hepatitis C), the protease inhibitors telaprevir and boceprevir, the nucleoside RNA replicase inhibitors (NRRIs) PSI-6130 and R1479, and various non-nucleoside RNA replicase inhibitors (NNRRIs); for the treatment of human immunodeficiency virus (HIV) infections, integrase inhibitors (INIs) such as elvitegravir, nucleoside reverse transcriptase inhibitors (NRTIs) such as apricitabine, non-nucleoside reverse transcriptase inhibitors (NNRTIs) such as rilpivirine and dapivirine; and for the treatment of both HCV and HIV infections, cyclosporin A derivatives such as the non-immunosuppressive Debio-025.

Publication types

  • Review

MeSH terms

  • Anti-HIV Agents / therapeutic use
  • Antiviral Agents / therapeutic use*
  • DNA Virus Infections / drug therapy
  • HIV Protease Inhibitors / therapeutic use
  • Hepatitis, Viral, Human / drug therapy
  • Humans
  • Integrase Inhibitors / therapeutic use
  • Protease Inhibitors / therapeutic use
  • RNA Virus Infections / drug therapy
  • Reverse Transcriptase Inhibitors / therapeutic use
  • Virus Diseases / drug therapy*


  • Anti-HIV Agents
  • Antiviral Agents
  • HIV Protease Inhibitors
  • Integrase Inhibitors
  • Protease Inhibitors
  • Reverse Transcriptase Inhibitors